New cell therapy offers hope for advanced ALS patients
NCT ID NCT06169176
Summary
This trial provides access to an experimental cell therapy called RAPA-501 for people with advanced ALS who cannot join other studies. Doctors collect a patient's own immune cells, reprogram them in a lab to reduce inflammation, and infuse them back into the patient up to four times. The main goals are to check if the treatment is safe and to see if it might help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Hospital Phoenix
Scottsdale, Arizona, 85259, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
University of California Irvine Health
Irvine, California, 92868, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.